Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Impact of Early Diagnosis and Treatment of OSA on Hospital Readmission in Hospitalized COPD Patients

NCT: NCT03647462 · WITHDRAWN

NCT IDNCT03647462
StatusWITHDRAWN
Start Date2017-06
Completion2017-09-06
SponsorKaiser Permanente (OTHER)
First posted
Last updated

Brief Summary

The purpose of this study is to determine whether early diagnosis of OSA and initiation of and adherence to CPAP therapy in patients hospitalized for chronic obstructive pulmonary disease reduce 30-day hospital readmission rates.

Frequently Asked Questions

What is Impact of Early Diagnosis and Treatment of OSA on Hospital Readmission in Hospitalized COPD Patients?

Impact of Early Diagnosis and Treatment of OSA on Hospital Readmission in Hospitalized COPD Patients is a clinical trial registered under NCT03647462. Current status: WITHDRAWN.

What is the status of NCT03647462?

The current status of NCT03647462 (Impact of Early Diagnosis and Treatment of OSA on Hospital Readmission in Hospitalized COPD Patients) is: WITHDRAWN.

When did Impact of Early Diagnosis and Treatment of OSA on Hospital Readmission in Hospitalized COPD Patients start?

Impact of Early Diagnosis and Treatment of OSA on Hospital Readmission in Hospitalized COPD Patients started on 2017-06.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑